FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167127116> ?p ?o ?g. }

• W3167127116 endingPage "TPS9137" @default.
• W3167127116 startingPage "TPS9137" @default.
• W3167127116 abstract "TPS9137 Background: Immune checkpoint inhibitors have led to durable remissions for some patients with advanced malignancies, including NSCLC; however, only a minority of patients benefit. The field of oncology is addressing this via the development of novel therapies, combinations and identification of biomarkers to select patients most likely to derive clinical benefit. ICOS, a novel therapeutic target, is a costimulatory molecule upregulated on activated T cells. Vopratelimab is an investigational IgG1 ICOS agonist monoclonal antibody that results in activation and proliferation of primed CD4 T effector cells. The preliminary efficacy of vopratelimab +/- nivolumab was assessed in the phase 1/2 ICONIC study in which durable responses were observed in a subset of patients who demonstrated on treatment emergence of peripheral ICOS hi CD4 T effector cells. Patients with peripheral ICOS hi CD4 T cells achieved significantly greater clinical benefit than patients whose CD4 T cells remained ICOS lo. An RNA based tumor inflammation signature (TIS) comprised of 18 genes associated with immune cell infiltration was previously identified as a predictive biomarker of response to anti-PD-1 therapy (Ayers et al, 2017); it was also associated with ICOS hi CD4 T cell emergence in ICONIC (ASCO-SITC 2020). The pre-treatment tumor TIS score, coupled with a specific threshold established by Jounce, referred to as TIS vopra , was predictive of ICOS hi CD4 T cell emergence. TIS vopra positive patients had improved RECIST response, PFS, and OS compared to those with a TIS vopra negative score. Therefore, we hypothesize that patient selection by TIS vopra will identify those who will display emergence of ICOS hi CD4 T cell populations and importantly, improved clinical outcomes when treated with vopratelimab in combination with JTX-4014 (a novel PD-1 inhibitor in development by Jounce) vs JTX-4014 alone. Methods: This Phase 2 open-label multicenter study is investigating JTX-4014 alone and in combination with vopratelimab in TIS vopra selected patients with metastatic NSCLC after one prior platinum-containing regimen (NCT04549025). Patients must be PD-1/L1 inhibitor naïve and negative for activating EGFR mutations. TIS vopra eligibility is determined using RNA isolated from a tumor sample. Eligible patients will be randomized to receive either JTX-4014 as monotherapy or in combination with one of two dose levels of vopratelimab. The primary endpoint is mean percent change from baseline tumor size of all measurable existing and new lesions averaged over 9 and 18 weeks. Secondary endpoints include ORR and PFS according to RECIST v1.1, OS, safety, and association of baseline TIS score with clinical outcomes. The study has a target enrollment goal of approximately 75 patients; the first patient was dosed October 2020. Clinical trial information: NCT04549025." @default.
• W3167127116 created "2021-06-22" @default.
• W3167127116 creator A5004058188 @default.
• W3167127116 creator A5004447476 @default.
• W3167127116 creator A5005602167 @default.
• W3167127116 creator A5007287881 @default.
• W3167127116 creator A5008600529 @default.
• W3167127116 creator A5008914563 @default.
• W3167127116 creator A5009675709 @default.
• W3167127116 creator A5017500875 @default.
• W3167127116 creator A5024821812 @default.
• W3167127116 creator A5025443187 @default.
• W3167127116 creator A5026454005 @default.
• W3167127116 creator A5028800670 @default.
• W3167127116 creator A5034794335 @default.
• W3167127116 creator A5059373950 @default.
• W3167127116 creator A5063905113 @default.
• W3167127116 creator A5064261996 @default.
• W3167127116 creator A5068278810 @default.
• W3167127116 creator A5068428294 @default.
• W3167127116 creator A5084413226 @default.
• W3167127116 creator A5084798468 @default.
• W3167127116 date "2021-05-20" @default.
• W3167127116 modified "2023-09-27" @default.
• W3167127116 title "Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT)." @default.
• W3167127116 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.tps9137" @default.
• W3167127116 hasPublicationYear "2021" @default.
• W3167127116 type Work @default.
• W3167127116 sameAs 3167127116 @default.
• W3167127116 citedByCount "2" @default.
• W3167127116 countsByYear W31671271162021 @default.
• W3167127116 countsByYear W31671271162022 @default.
• W3167127116 crossrefType "journal-article" @default.
• W3167127116 hasAuthorship W3167127116A5004058188 @default.
• W3167127116 hasAuthorship W3167127116A5004447476 @default.
• W3167127116 hasAuthorship W3167127116A5005602167 @default.
• W3167127116 hasAuthorship W3167127116A5007287881 @default.
• W3167127116 hasAuthorship W3167127116A5008600529 @default.
• W3167127116 hasAuthorship W3167127116A5008914563 @default.
• W3167127116 hasAuthorship W3167127116A5009675709 @default.
• W3167127116 hasAuthorship W3167127116A5017500875 @default.
• W3167127116 hasAuthorship W3167127116A5024821812 @default.
• W3167127116 hasAuthorship W3167127116A5025443187 @default.
• W3167127116 hasAuthorship W3167127116A5026454005 @default.
• W3167127116 hasAuthorship W3167127116A5028800670 @default.
• W3167127116 hasAuthorship W3167127116A5034794335 @default.
• W3167127116 hasAuthorship W3167127116A5059373950 @default.
• W3167127116 hasAuthorship W3167127116A5063905113 @default.
• W3167127116 hasAuthorship W3167127116A5064261996 @default.
• W3167127116 hasAuthorship W3167127116A5068278810 @default.
• W3167127116 hasAuthorship W3167127116A5068428294 @default.
• W3167127116 hasAuthorship W3167127116A5084413226 @default.
• W3167127116 hasAuthorship W3167127116A5084798468 @default.
• W3167127116 hasConcept C121608353 @default.
• W3167127116 hasConcept C126322002 @default.
• W3167127116 hasConcept C143998085 @default.
• W3167127116 hasConcept C167672396 @default.
• W3167127116 hasConcept C185592680 @default.
• W3167127116 hasConcept C203014093 @default.
• W3167127116 hasConcept C2776090121 @default.
• W3167127116 hasConcept C2777701055 @default.
• W3167127116 hasConcept C2780030458 @default.
• W3167127116 hasConcept C2781197716 @default.
• W3167127116 hasConcept C502942594 @default.
• W3167127116 hasConcept C55493867 @default.
• W3167127116 hasConcept C71924100 @default.
• W3167127116 hasConcept C8891405 @default.
• W3167127116 hasConceptScore W3167127116C121608353 @default.
• W3167127116 hasConceptScore W3167127116C126322002 @default.
• W3167127116 hasConceptScore W3167127116C143998085 @default.
• W3167127116 hasConceptScore W3167127116C167672396 @default.
• W3167127116 hasConceptScore W3167127116C185592680 @default.
• W3167127116 hasConceptScore W3167127116C203014093 @default.
• W3167127116 hasConceptScore W3167127116C2776090121 @default.
• W3167127116 hasConceptScore W3167127116C2777701055 @default.
• W3167127116 hasConceptScore W3167127116C2780030458 @default.
• W3167127116 hasConceptScore W3167127116C2781197716 @default.
• W3167127116 hasConceptScore W3167127116C502942594 @default.
• W3167127116 hasConceptScore W3167127116C55493867 @default.
• W3167127116 hasConceptScore W3167127116C71924100 @default.
• W3167127116 hasConceptScore W3167127116C8891405 @default.
• W3167127116 hasFunder F4320316843 @default.
• W3167127116 hasIssue "15_suppl" @default.
• W3167127116 hasLocation W31671271161 @default.
• W3167127116 hasOpenAccess W3167127116 @default.
• W3167127116 hasPrimaryLocation W31671271161 @default.
• W3167127116 hasRelatedWork W1996150995 @default.
• W3167127116 hasRelatedWork W2122932058 @default.
• W3167127116 hasRelatedWork W2387430262 @default.
• W3167127116 hasRelatedWork W2979416044 @default.
• W3167127116 hasRelatedWork W2980446793 @default.
• W3167127116 hasRelatedWork W3167775801 @default.
• W3167127116 hasRelatedWork W3215044659 @default.
• W3167127116 hasRelatedWork W4206284710 @default.
• W3167127116 hasRelatedWork W4322616502 @default.
• W3167127116 hasRelatedWork W4360983034 @default.
• W3167127116 hasVolume "39" @default.
• W3167127116 isParatext "false" @default.

• next